| Literature DB >> 20615861 |
Hugh MacPherson1, Douglas G Altman, Richard Hammerschlag, Youping Li, Taixiang Wu, Adrian White, David Moher.
Abstract
The STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) were published in five journals in 2001 and 2002. These guidelines, in the form of a checklist and explanations for use by authors and journal editors, were designed to improve reporting of acupuncture trials, particularly the interventions, thereby facilitating their interpretation and replication. Subsequent reviews of the application and impact of STRICTA have highlighted the value of STRICTA as well as scope for improvements and revision. To manage the revision process a collaboration between the STRICTA Group, the CONSORT Group and the Chinese Cochrane Centre was developed in 2008. An expert panel with 47 participants was convened that provided electronic feedback on a revised draft of the checklist. At a subsequent face-to-face meeting in Freiburg, a group of 21 participants further revised the STRICTA checklist and planned dissemination. The new STRICTA checklist, which is an official extension of CONSORT, includes 6 items and 17 subitems. These set out reporting guidelines for the acupuncture rationale, the details of needling, the treatment regimen, other components of treatment, the practitioner background and the control or comparator interventions. In addition, and as part of this revision process, the explanations for each item have been elaborated, and examples of good reporting for each item are provided. In addition, the word 'controlled' in STRICTA is replaced by 'clinical', to indicate that STRICTA is applicable to a broad range of clinical evaluation designs, including uncontrolled outcome studies and case reports. It is intended that the revised STRICTA checklist, in conjunction with both the main CONSORT statement and extension for non-pharmacological treatment, will raise the quality of reporting of clinical trials of acupuncture.Entities:
Mesh:
Year: 2010 PMID: 20615861 PMCID: PMC3002761 DOI: 10.1136/aim.2009.001370
Source DB: PubMed Journal: Acupunct Med ISSN: 0964-5284 Impact factor: 2.267
Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) items that replace CONSORT 2010 item 5 when reporting an acupuncture trial
| (1) Acupuncture rationale | (1a) Style of acupuncture (eg, Traditional Chinese Medicine, Japanese, Korean, Western medical, Five Element, ear acupuncture, etc) |
| (1b) Reasoning for treatment provided, based on historical context, literature sources and/or consensus methods, with references where appropriate | |
| (1c) Extent to which treatment was varied | |
| (2) Details of needling | (2a) Number of needle insertions per subject per session (mean and range where relevant) |
| (2b) Names (or location if no standard name) of points used (uni-/bilateral) | |
| (2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level | |
| (2d) Responses sought (eg, de qi or muscle twitch response) | |
| (2e) Needle stimulation (eg, manual or electrical) | |
| (2f) Needle retention time | |
| (2g) Needle type (diameter, length and manufacturer or material) | |
| (3) Treatment regimen | (3a) Number of treatment sessions |
| (3b) Frequency and duration of treatment sessions | |
| (4) Other components of treatment | (4a) Details of other interventions administered to the acupuncture group (eg, moxi bustion, cupping, herbs, exercises, lifestyle advice) |
| (4b) Setting and context of treatment, including instructions to practitioners, and information and explanations to patients | |
| (5) Practitioner background | (5) Description of participating acupuncturists (qualification or professional affiliation, years in acupuncture practice, other relevant experience) |
| (6) Control or comparator interventions | (6a) Rationale for the control or comparator in the context of the research question, with sources that justify the choice(s) |
| (6b) Precise description of the control or comparator. If sham acupuncture or any other type of acupuncture-like control is used, provide details as for items 1–3 above |
This checklist should be read in conjunction with the explanations of the Standards for Reporting Interventions in Clinical Trials of Acupuncture items provided in the main text.
Checklist of CONSORT items and the non-pharmacological trials extension to CONSORT (with STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) extending CONSORT item 5 for acupuncture trials)
| Section/topic | Item number | CONSORT 2010 statement | Additional items from the non-pharmacological trials extension to CONSORT |
|---|---|---|---|
| Title and abstract | 1a | Identification as a randomised trial in the title | In the abstract, description of the experimental treatment, comparator, care providers, centres and blinding status |
| 1b | Structured summary of trial design, methods, results and conclusions; for specific guidance, see CONSORT for abstracts | ||
| Introduction | |||
| Background and objectives | 2a | Scientific background and explanation of rationale | – |
| 2b | Specific objectives or hypotheses | ||
| Methods | |||
| Trial design | 3a | Description of trial design (eg, parallel, factorial) including allocation ratio | |
| 3b | Important changes to methods after trial commencement (eg, eligibility criteria), with reasons | ||
| Participants | 4a | Eligibility criteria for participants | When applicable, eligibility criteria for centres and those performing the interventions |
| 4b | Settings and locations where the data were collected | ||
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | Precise details of both the experimental treatment and comparator–see |
| Outcomes | 6a | Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed | – |
| 6b | Any changes to trial outcomes after the trial started with reasons | ||
| Sample size | 7a | How sample size was determined | When applicable, details of whether and how |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | the clustering by care providers or centres was addressed | |
| Randomisation | |||
| Sequence generation | 8a | Method used to generate the random allocation sequence | When applicable, how care providers were |
| 8b | Type of randomisation; details of any restriction (eg, blocking and block size) | allocated to each trial group | |
| Allocation concealment | 9 | Mechanism used to implement the random allocation sequence (eg, sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | – |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | – |
| Blinding | 11a | If done, who was blinded after assignment to interventions (eg, participants, care providers, those assessing outcomes) and how | Whether or not those administering co-interventions were blinded to group assignment |
| 11b | If relevant, description of the similarity of interventions | If blinded, method of blinding and description of the similarity of interventions | |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | When applicable, details of whether and how the clustering by care providers or centres was addressed |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | ||
| Results | |||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment and were analysed for the primary outcome | The number of care providers or centres performing the intervention in each group and the number of patients treated by each care provider or in each centre |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | ||
| Implementation of intervention | – | – | Details of the experimental treatment and comparator as they were implemented |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | – |
| 14b | Why the trial ended or was stopped | ||
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | When applicable, a description of care providers (case volume, qualification, expertise, etc) and centres (volume) in each group |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | – |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group and the estimated effect size and its precision (eg, 95% CI) | – |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | ||
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory | – |
| Harms | 19 | All important harms or unintended effects in each group; for specific guidance see CONSORT for Harms | – |
| Discussion | |||
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision and, if relevant, multiplicity of analyses | |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings | Generalisability (external validity) of the trial findings according to the intervention, comparators, patients and care providers and centres involved in the trial |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | In addition, take into account the choice of the comparator, lack of or partial blinding, unequal expertise of care providers or centres in each group |
| Other information | |||
| Registration | 23 | Registration number and name of trial registry | |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | |
| Funding | 25 | Sources of funding and other support (eg, supply of drugs); role of funders | |
We strongly recommend reading this statement in conjunction with the CONSORT 2010 explanation and elaboration11 for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials,61 non-inferiority and equivalence trials,62 herbal interventions,63 and pragmatic trials.16 Moreover, additional extensions are forthcoming. See http://www.consort-statement.org (accessed April 2010), for those and also for up-to-date references relevant to this checklist.